NCT02142803 · OUTCOME

Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (R2PD) of Daily Oral MLN0128 When Administered With Bevacizumab

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: mg/day
Interval / dispersion: Not reported
Time frame: 28 days

What was measured

Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (R2PD) of TORC1/2 inhibitor MLN0128, determined according to incidence of dose-limiting toxicity, as graded using the National Cancer Institute (NCI) CTCAE version 4.0

Groups in this outcome

Stage 1: Dose Escalation to Estimate MTD/RP2D

Participants enrolled onto Stage 1 - Dose escalation to estimate MTD/RP2D

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Stage 1: Dose Escalation to Estimate MTD/RP2D	12

Reported measurements

Source class 1

Values in mg/day · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Stage 1: Dose Escalation to Estimate MTD/RP2D	5	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
5

denoms

counts
group Id
OG000
value
12
units
Participants

description

groups

description
Participants enrolled onto Stage 1 - Dose escalation to estimate MTD/RP2D
id
OG000
title
Stage 1: Dose Escalation to Estimate MTD/RP2D

param Type

NUMBER

reporting Status

POSTED

time Frame

28 days

title

Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (R2PD) of Daily Oral MLN0128 When Administered With Bevacizumab

type

PRIMARY

unit Of Measure

mg/day

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice